Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Vir makes solid tumor T cell engager deal with Gilead

Vir Biotechnology and its CEO Marianne De Backer have notched yet another deal, this time with Gilead. Gilead will pay Vir $65 million upfront, with another $45 million in near-term milestones. Gilead's also paying a ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Wednesday 14 October →